1. Introduction {#sec0005}
===============

The innate immunity is the first line of defence against viral infections. It allows infected and neighbour cells to establish an antiviral state in the host early after virus exposure and prepares the adaptive immune response. This antiviral response is initiated upon recognition of viral molecular signatures by specialized cellular receptors, which in turn activates signalling cascades that ultimately culminate in the production of antiviral factors.

1.1. Type I IFN: a key cytokine of the innate antiviral immunity {#sec0010}
----------------------------------------------------------------

In 1957, Isaacs and Lindenmann observed that the culture medium of cells infected with an inactive influenza virus could protect naive cells against virulent infection ([@bib0405]). This result indicated that the culture medium was containing a protective substance able to interfere with viral dissemination that was subsequently named "interferon" (IFN). Since its original discovery, many types of IFNs have been identified that are now classified into three distinct families: type I, type II and type III IFNs.

Type I IFNs are ubiquitously expressed cytokines that are conserved among vertebrates. They are divided into several classes including IFN-α, IFN-β, IFN-κ, IFN-ɛ and IFN-ω, IFN-α/β being the major key players. All these cytokines are structurally and genetically related as they derive from common ancestors ([@bib0755], [@bib0690], [@bib0085]). In humans, there are 13 different IFN-α genes while all the other type I IFNs are encoded by only one gene. IFN-τ and IFN-δ are absent in humans. In ruminants however, several subtypes of IFN-β have been described ([@bib0690]) and IFN-τ plays a crucial role during gestation ([@bib0320]). Type I IFNs do not display antiviral properties *per se* but are mediators that propagate signals within and between cells to induce the expression of antiviral effectors ([@bib0690]). They also exhibit antiproliferative and proapoptotic properties and are prone to shape the immune adaptive response. They contribute to the maturation of dendritic cells (DC), the cytotoxicity of natural killer (NK) cells, the differentiation of T cytotoxic lymphocytes and to the production of high antibody titres upon viral infections ([@bib0180]). Because of all these properties, IFNs are considered as crucial cytokines to circumvent viral propagation early during infection and to achieve the switch between the host innate and adaptive responses.

Besides type I IFNs, two other IFN families exist, type II (IFN-γ) and type III (IFN-λ) IFNs, that will not be discussed in details in this review. IFN-γ is expressed in cells of the immune system such as lymphocytes and NK cells. It participates to the induction and the regulation of the immune response by activating immune cells and favouring antigen presentation. It also contributes to cell proliferation and activation of apoptosis ([@bib0825]). Its expression is induced by a variety of cytokines including IL-12 and IL-18 that are produced during viral infections. IFN-λ (IL-28A, IL-28B and IL-29) were discovered more recently. They share many common features with IFN-α/β and regulate similar clusters of genes although they use a distinct receptor ([@bib0030], [@bib0500]). *In vivo*, the difference between these two types of IFNs relies mainly on the distinct tissue-specific expression of their dedicated receptors. Indeed, IFN-λ expression is restricted to immune and epithelial cells while type I IFNs are ubiquitously expressed ([@bib0860]).

The IFN signalling pathway is divided into two phases: (1) an induction phase triggered by the detection of viral molecules by specialized cellular receptors leading to a first wave of IFN synthesis; (2) a response phase activated upon IFN binding to its cognate receptor and characterized by the expression of hundreds of genes involved in the establishment of an antiviral state. In a first part, we will review the different steps involved in the production and function of IFN-α/β and will give some examples of mechanisms evolved by viruses to counteract these pathways. Then, we will give insights into the mechanisms of IFN-α/β induction during BTV infection and will describe the recently uncovered role of NS3 of BTV as a type I IFN antagonist.

### 1.1.1. Induction of type I IFN synthesis in response to virus infection {#sec0015}

The production of IFN in response to virus intrusion is triggered by the recognition of pathogen associated molecular patterns (PAMPs) by the infected cell. There are four main types of viral PAMPs: dsRNA, ssRNA, non-methylated CpG DNA and envelop glycoproteins. The detection of these viral molecules is accomplished by specialized receptors named pattern recognition receptors (PRRs). These receptors or sensors have two essential functions: (1) to discriminate between self and non-self molecules and (2) to promote an antimicrobial response towards multiple pathogens. The two best characterized families of PRRs involved in the detection of viruses are the Toll-like receptors (TLRs) and the RIG-I-like receptors (RLRs).

#### 1.1.1.1. Extracellular receptors of viral PAMPs: the TLRs family {#sec0020}

Thirteen members of the TLR family have been identified to date, each one being involved in the detection of distinct patterns ([@bib0900], [@bib0015], [@bib0920]). TLRs are expressed mainly by antigen presenting cells like DCs or macrophages. However, their expression is not restricted to these cells and most host cells can express at least some TLRs ([@bib0010]). Moreover, expression of TLRs can be induced by many pathogens, cytokines or cellular stresses. Although they recognize diverse molecular structures, TLRs share a common structural organization with a leucine-rich extracellular domain (LRR) which is required for PAMPs recognition, a transmembrane hydrophobic domain and a cytosolic signalling domain, called TIR (Toll/interleukin-1 receptor) domain which mediates homotypic interactions with adaptor proteins containing a TIR domain ([@bib0015], [@bib0445], [@bib0065]). TLRs are key actors in the antiviral response, especially in plasmacytoid DCs (pDCs) that are among the main IFN producing cells of the organism. TLR3, TLR7/8 and TLR9 are the most important TLRs for the detection of viral infections and are all specialized in the recognition of nucleic acids ([@bib0465], [@bib0205]). Interestingly, these TLRs are localized in endosomal compartments with the exception of TLR3 which is also expressed at the surface of human fibroblasts ([@bib0015], [@bib0975]). The binding of ligand to its dedicated TLR provokes the dimerization and a conformational change of the receptor, and the subsequent recruitment of specific adaptive molecules: MyD88 for TLR7-9 and TRIF/TICAM1 for TLR3. These adaptors coordinate the activation of multiple signalling pathways that contribute to the synthesis of IFN-α/β and pro-inflammatory cytokines ([@bib0665]).

*TLR3*. Until recently, dsRNA was considered as the main viral PAMP. It is contained in the genome of certain viruses such as members of the *Reoviridae* family, appears transiently as intermediates of replication or represents structured RNA generated during most viral infections. Interaction of TLR3 with dsRNA or poly(I:C), a synthetic analogue of dsRNA, allows the recruitment of a unique adaptor, TRIF, that activates the transcription factors IRF-3/7, NF-κB and AP-1 ([@bib0020], [@bib1005], [@bib0975]). IRF-3 and IRF-7 essentially control the expression of IFN-α/β genes, while NF-κB and AP-1 regulate various genes encoding inflammatory cytokines. TRIF interacts with TRAF3, a member of the TRAF family, which in turn activates TBK1 and IKKɛ kinases ([@bib0300], [@bib0670]). The activation of these kinases is also controlled by other proteins such as TANK, SINTBAD or NEMO within a large complex ([@bib0780], [@bib1055]). TBK1 and IKKɛ phosphorylate IRF-3 and IRF-7 transcription factors which consequently dimerize and translocate into the nucleus to activate the transcription of IFN-α/β genes ([@bib0675]). IRF-3 is constitutively expressed and can be engaged early upon viral infection. In contrast, IRF-7 is poorly expressed at basal level but is highly induced upon IFN release, thus playing a key role in the second wave of IFN synthesis ([@bib0375], [@bib0355]). TRIF adaptor associates with TRAF6, an E3 ubiquitin ligase, and RIP1 which is involved in the activation of NF-κB mediated by the TNF receptor. These two proteins activate the MAPK (JNK, p38) pathway which governs the activation of members of the AP-1 family (ATF2/c-Jun) and the IKK complex (α/β/γ-NEMO). Activation of this complex leads to the phosphorylation and the subsequent degradation of the IκBα inhibitor, allowing NF-κB (p65/p50) to translocate into the nucleus to induce a pro-inflammatory response. The TLR3/TRIF signalling pathway appears essential in certain types of cells such as conventional DCs (cDCs) where TLR3 is highly expressed. Nevertheless, the role of this sensor appears negligible for the innate antiviral response in most cases although a physiological relevance of TLR3 has been suggested for some viruses like encephalomyocarditis virus (EMCV), herpes simplex virus type-1 (HSV-1) or respiratory syncytial virus (RSV) ([@bib0325], [@bib1045], [@bib0975]).

*TLR7/8*. TLR7 and TLR8 (7/8) are highly homologous and both use ssRNA as ligand ([@bib0335], [@bib0015], [@bib0205], [@bib0960]). They are highly expressed in pDCs. The induction of IFN-α/β synthesis in response to the activation of these PRRs occurs through the specific activation and homodimerization of IRF-7 which induces the expression of most IFN-α genes. Interestingly, while IRF-7 is inducible in most cell types, it is constitutively expressed in pDCs, suggesting this sensor plays a major role in these cells. Upon ssRNA binding in endosomal compartments, TLR7/8 recruits the adaptive molecule MyD88 through its TIR domain. Then, MyD88 forms a complex with IRAK-4 and IRAK-1 kinases that trigger the activation of the IRF-7 and NF-κB pathways with the involvement of other factors including TRAF3 and TRAF6 ([@bib0470], [@bib0375], [@bib0300], [@bib0670]).

*TLR9*. The TLR9 receptor detects unmethylated dinucleotides CpG DNA molecules from bacterial or viral origin ([@bib0345], [@bib0205]). Several genomes from DNA viruses like HSV-1/2, Epstein--Barr virus and murine cytomegalovirus (MCMV) have been described as TLR9 stimulators ([@bib0570], [@bib0360], [@bib0885], [@bib0230]). The TLR9 pathway is very similar to the one triggered by TLR7/8 and appears highly active in pDCs.

*TLRs and viral proteins*. Not only nucleic acids but also viral proteins are able to activate TLRs ([@bib0920], [@bib0960]). For example, the F protein of RSV ([@bib0510]) and the G glycoprotein of vesicular stomatitis virus activate TLR4. In parallel, TLR2 can also induce cellular responses upon binding to viral proteins such as measles haemaglutinin (H), hepatitis C virus (HCV) core and NS3 proteins or gB and gH envelop glycoproteins of human CMV ([@bib0075]).

#### 1.1.1.2. Cytosolic receptors of viral PAMPs {#sec0025}

As depicted above, TLRs constitute an efficient alert system in case of pathogen intrusion and allow the infected cells to initiate a rapid and strong antimicrobial response. However, the main limit of action of these cellular sentinels is linked to their distribution: TLRs are localized at the cell surface or within endosomal compartments and are thus unable to sense intracytoplasmic viruses. Moreover, TLRs are expressed mainly in immune cells and therefore seem to play a minor role in most cell types. Finally, the use of models in which the activation or expression of TLRs is impaired or absent has strengthened the hypothesis that an alternative system exists for the intracellular detection of viral replication.

*The RIG-I-like receptor pathway*. Two studies have identified RIG-I and MDA5 helicases as intracellular PRRs able to induce the production of IFN-α/β and inflammatory cytokines in response to the presence of dsRNA in the cytoplasm ([@bib0025], [@bib1030]). These helicases share many similar features and were named RIG-I like receptors (RLRs). They contain a DExD/H type helicase domain, a C-terminal domain (CTD) which is involved in the detection of nucleic acids, a repressor domain (RD) -- absent in MDA5 -- and two CARD domains at the amino-terminus end that are essential for signalling ([@bib0170], [@bib0895]). Expression of the CARD region alone is sufficient to trigger type I IFN production. RIG-I and MDA5 are expressed ubiquitously in most tissues and are induced by IFN, allowing an autocrine and paracrine amplification of this detection system. However, while RIG-I is crucial for the induction of IFN-α/β after infection with RNA viruses in fibroblasts and most subsets of conventional DCs (cDCs), plasmacytoid DCs (pDCs) preferentially use the TLR system ([@bib0450], [@bib0560]). The activity and stability of the RLRs is well controlled by regulating proteins including TRIM25 and RNF125 ([@bib0035], [@bib0255]). Although RIG-I and MDA5 share high sequence identity, they are activated by different RNA subsets ([@bib0790]). RIG-I displays higher affinity for ssRNA than dsRNA ([@bib0800], [@bib0895]). Among ssRNA, those containing a 5′-triphosphate bind RIG-I with a very high affinity and strongly induce IFN-α/β synthesis ([@bib0380], [@bib0695], [@bib0715], [@bib0795], [@bib0170], [@bib0895]). These types of 5′ triphosphate RNAs are generally absent from non-infected cells making the 5′-triphosphate motif a major viral PAMP. RIG-I is also activated by transcripts generated by the T7 RNA polymerase as well as influenza genomic RNA ([@bib0740]). More recent data have indicated that RIG-I activation can be influenced by many characteristics including secondary structure, the presence of "panhandle" structure, nucleosidic modifications and sequences ([@bib0595], [@bib0800], [@bib0895], [@bib0815], [@bib0890], [@bib0555]). RIG-I has been described as a RNA sensor for many viruses including Flaviviviruses, Orthomyxoviruses, Paramyxoviruses and Rhabdoviruses ([@bib0380], [@bib0460], [@bib0715], [@bib0170]). Recent additional structural data have also given insights into the mode of binding and activation of RIG-I ([@bib0170], [@bib0895]) (reviewed in ([@bib0490])). The mode of recognition of non-self RNA by MDA5 is less clear. *In vivo*, MDA5 was described as a sensor for poly(I:C) and members of the *Picornaviridae* family ([@bib0275], [@bib0460]). MDA5 do not bind 5′-triphosphate RNAs but has a high affinity for dsRNA. Interestingly, while RIG-I preferentially recognizes ssRNA, it can also associates and is activated by short dsRNA (\<2 kb). In contrast, long dsRNA molecules (\>2 kb) are necessary for MDA5 activation ([@bib0455]). Members of the *Reoviridae* family that possess dsRNA genomes segments ranging from 1.2 to 3.9 kb can then activate both helicases ([@bib0455]). Members of the *Flaviridae* family are also able to activate RIG-I and MDA5 ([@bib0240]). A third RLR member, LGP2, has also been described. LGP2 is highly homologous to RIG-I and MDA5 but lacks the CARD signalling domain ([@bib1025]). LGP2 was originally considered as a negative regulator of the RLR pathway but its role in the antiviral response seems more complex and virus-dependent ([@bib0760], [@bib1025], [@bib0495], [@bib0795], [@bib0970], [@bib0990], [@bib0805]).

In the absence of stimulating RNA molecules, RIG-I is maintained in a closed inactive conformation by the RD domain ([@bib0795], [@bib0990]). Binding of viral RNA onto the CTD domain of the protein induces a conformational change that allows CARDs exposure and activation of the helicase domain. RIG-I can then multimerize and interact with the mitochondrial adaptor protein MAVS (*Mitochondrial antiviral signalling*, also named IPS-1, VISA, CARDIF) ([@bib0475], [@bib0645], [@bib0840], [@bib1000]). This interaction occurs through a homotypic interaction between the CARD region of RIG-I and a CARD domain present at the amino-terminus of MAVS. Upon dsRNA binding, MDA5 forms dimers and filaments, a step required for subsequent association with MAVS ([@bib0060]). Like TRIF, MAVS interacts with TRAF3 ([@bib0785]) to activate TBK1 and IKKɛ and subsequently IRF-3/7 transcription factors. In parallel, activation of the NF-κB pro-inflammatory pathway is ensured by other adaptors including FADD/RIP1 and/or members of the TRAF family ([@bib0475], [@bib0840], [@bib1000]). Interaction of MAVS with STING, a protein anchored at the endoplasmic reticulum, has been described and may also play a role in IFN-α/β induction ([@bib0475], [@bib0410], [@bib0040]). Some other sensors may also play a role in RNA sensing but are less characterized. Among those, a complex made of the DDX1, DDX21 and DHX36 helicases recognizes dsRNA in mDCs and uses TRIF to induce the signalling cascade leading to IFN-α/β production ([@bib1050]). Many cytoplasmic DNA receptors have also been described but will not be discussed here ([@bib0955]).

### 1.1.2. Response to type I IFN {#sec0030}

The best-characterized pathway triggered by the secretion of type I IFN is the Janus tyrosine kinase (JAK)/signal transducer and activator of transcription protein (STAT) signalling pathway that was first described in the 1990s and is functional in most cell types ([@bib0245], [@bib0810], [@bib0850], [@bib0700]). Activation of this pathway leads to the expression of hundreds of proteins encoded by IFN-stimulated genes (ISGs) that act on cellular processes such as the innate and adaptive immune system, cellular proliferation and survival and protein synthesis to establish an antiviral state within the cell. Once IFN-α/β is secreted into the extracellular compartment, it binds to its cell surface receptor called IFNAR. IFNAR is composed of two transmembrane sub-units, IFNAR1 and IFNAR2, that are expressed in most tissues ([@bib0175]). IFNAR1 is constitutively associated with tyrosine kinase 2 (TYK2) ([@bib0155], [@bib0165], [@bib0265]), a kinase belonging to the JAK family and IFNAR2 is pre-associated with JAK1 and STAT2 ([@bib0940]). Interaction of type I IFN with one subunit of IFNAR leads to the recruitment of the other subunit ([@bib0515]) and their subsequent dimerization. This initial step triggers the phosphorylation of TYK2 on tyrosine 1054 and/or 1055 *via* a mechanism dependent on JAK1 ([@bib0850], [@bib0265], [@bib0505]). Tyk2 then phosphorylates JAK1 to activate it further (putative tyrosine 1022/1023). The activated kinases subsequently phosphorylate tyrosine residues located in the cytoplasmic domain of IFNAR1 (tyrosine 466) and IFNAR2 (tyrosine 510) ([@bib0705], [@bib0005], [@bib0710], [@bib0505], [@bib1060]). STAT2 is then able to bind to the phosphorylated residue of IFNAR1 and is phosphorylated by the JAK kinases on tyrosine 690. STAT1 subsequently binds through its SH2 domain to the newly phosporylated tyrosine of STAT2 and becomes phosphorylated on tyrosine 701 ([@bib0505], [@bib1010]). The activated STAT1/STAT2 dimer is then released from IFNAR2 and associates in the cytoplasm with IRF9 to form the transcription factor ISG factor 3 (ISGF3). This heterotrimeric complex migrates to the nucleus where it binds to specific promoter elements called IFN-stimulated response elements (ISRE) and initiates the transcription of ISGs.

Other STATs such as STAT3, STAT4, STAT5 and STAT6 can be activated by type I IFN but this activation is mainly specific to certain cell types such as endothelial cells, T lymphocytes or lymphoblasts ([@bib0055], [@bib0625], [@bib0215], [@bib0615], [@bib0925]). Different combinations of STAT homo- or hetero-dimers other than STAT1--STAT2 can then form. They bind to IFN-γ-activated site (GAS) elements present in the promoter of certain ISG and induce the transcription of distinct genes. These different STAT complexes have different functions such as the regulation of the type I IFN response, the production of IFN-γ or the promotion of cell growth.

Many mechanisms are present within a cell to regulate the JAK/STAT pathway. Some post-translational biochemical modifications of STAT and JAK proteins by phosphorylation, ubiquitination, acetylation, methylation, ISGylation and sumoylation are important for full transcriptional activation or regulation of the JAK/STAT pathway ([@bib0845]). Several key regulatory proteins are also expressed to regulate STAT and JAK proteins. They include protein tyrosine phosphatases (PTP), suppressor of cytokine signalling (SOCS) and protein inhibitor of activated STAT1 (PIAS) proteins.

Type I IFN can trigger other signalling cascades such as the mitogen activated protein kinase (MAPK), the phosphoinositide 3-kinase (PI3K), the v-crk sarcoma virus CT10 oncogene homolog (avian)-like (CRKL) and the NF-κB pathways. Additionally, activation of JAK results in the activation of several MAPK such as p38 and extracellular signal regulated kinases (ERK) that display antiviral activity and control cell differentiation and growth.

### 1.1.3. Function of ISGs {#sec0035}

Type I IFN induces the expression of hundreds of genes involved in multiple cellular processes. These genes encode proteins that possess an intrinsic antiviral activity, act directly on different signalling cascades involved in the type I IFN system to enhance its action and/or play a role in other cellular responses such as apoptosis. The best-characterized antiviral proteins induced by type I IFN are dsRNA-dependent protein kinase R (PKR), myxovirus resistance (Mx) proteins and 2′,5′-oligoadenylate synthetase (OAS) proteins. Other proteins thought to play an important role in this antiviral response include ISG15, ISG20, members of the tripartite motif (TRIM) family (PML) and proteins encoded by the *ISG56* (*IFIT1*) family of genes ([@bib0545]).

PKR is a serine/threonine kinase consisting of an amino-terminal regulatory domain containing two dsRNA binding site and a carboxy-terminal catalytic domain ([@bib0640]). In response to viral or synthetic dsRNA or other stimuli, PKR undergoes a conformational change leading to the activation of its kinase domain. Activated PKR phosphorylates eukaryotic initiation factor 2α-subunit (eIF2α) and subsequently blocks the translation of cellular and viral mRNA ([@bib0995]). As PKR is able to detect dsRNA, the kinase was first considered as a sensor for viral infections capable to induce the production of type I IFN ([@bib1020], [@bib0195], [@bib0270], [@bib0620]). Nevertheless, the importance of PKR as a sensor for the induction of type I IFN remains unclear and seems to be less crucial than RIG-I and MDA5 ([@bib0855]). Another antiviral mechanism triggered by the type I IFN system is the recognition of dsRNA by OAS. The enzyme directly binds to viral dsRNA and is activated to synthesize 2′,5′-linked oligoadenylates from ATP, leading to the dimerization and activation of ribonuclease L (RNase L) ([@bib0200], [@bib0590]). RNase L cleaves cellular and viral ssRNA downstream UU and UA sequences and generates small, often duplex, RNA ([@bib0590]). This action limits viral replication and packaging as well as host and viral protein synthesis. Mx proteins (MxA and MxB in humans, Mx1 and Mx2 in mice) are guanosine triphosphatases (GTPase) belonging to the dynamin family able to inhibit early stage of the replication cycle of a wide range of viruses. They are conserved among the majority of vertebrate species but all of them do not seem to have an antiviral activity. Their mode of action is still not completely understood but seems to involve the confinement of essential viral components necessary for viral replication to block their functions ([@bib0310], [@bib0315]).

The proteins described above are only examples as the expression of more than 380 ISGs are induced by type I IFN ([@bib0820]). Many of them play a role in the initiation of rapid, robust and efficient cellular responses interfering with the establishment of viral infections.

### 1.1.4. Immunomodulation properties of type I IFN {#sec0040}

The role of type I IFN is not restricted to the establishment of an antiviral state within cells as the cytokine is also involved in the modulation of many responses of the innate and adaptive immune system. Type I IFN can act directly on immune cells *via* the activation of IFNAR or indirectly *via* the induction of other cytokines and chemokines and the stimulation of specific cells ([@bib0080], [@bib0870], [@bib0350], [@bib0390]). Type I IFN is able to regulate natural killer (NK) cells by enhancing their ability to kill target cells and by stimulating their proliferation *via* the induction of IL-15 ([@bib0660]). Type I IFN also modulates the activity of macrophages and antigen-presenting cells such as pDCs and enhances the expression on these cells of surface receptors and co-stimulatory molecules that interact with immune cells of the adaptive response. For example, type I IFN enhances the expression of major histocompatibility complex (MHC) class I and proteins involved in antigen processing and presentation to increase antigen recognition and CD8 T-cell responses. Type I IFN is also directly involved in the survival, proliferation and differentiation of T cells into memory and effector T cells ([@bib0930]). Additionally, type I IFN modulates antiviral responses mediated by B lymphocytes *via* direct and indirect mechanisms by affecting their ability to produce cytotoxic and neutralizing antibodies and promoting their survival and activation ([@bib0480]).

1.2. Modulation of the type I IFN pathway by viruses {#sec0045}
----------------------------------------------------

As described above, viral infections can trigger rapidly an antiviral state in host cells to circumvent virus propagation. In order to limit this cellular response, viruses have evolved a great variety of escape mechanisms to counteract the IFN pathway at the synthesis as well as the response level, thus demonstrating the physiological importance of this pathway. Certain viruses and viral proteins have the ability to interfere at multiple levels of the IFN signalling to increase the efficiency of this evasion. Some viruses also act more globally by inducing a large transcriptional shut-off that blocks the expression of ISGs and genes involved in IFN signalling ([@bib0305]). The list of mechanisms described below is not exhaustive and many other strategies have been evolved by viruses to counteract the IFN system, illustrating the great capacity of viruses to fight the innate cellular response of the host. This topic has been thoroughly discussed in recent reviews ([@bib0305], [@bib0090], [@bib0520], [@bib0915]) and only a few examples of counteracting measures are given below.

### 1.2.1. Inhibition of type I IFN synthesis {#sec0050}

The initial step in the production of type I IFN requires the detection of viral PAMPs by PRRs. These cellular sensors are thus the first line of defence of the antiviral response and their activation constitutes relevant targets for viruses. One frequent strategy adopted by many RNA viruses resides in the protection of their nucleic acids inside protein structures or cellular compartments that render them inaccessible to cellular sensors ([@bib0730]). Certain viruses can avoid detection of the 5′ moiety of their genomic or mRNA molecules by specialized PRRs *via* capping events or 5′ triphosphate cleavage. Vaccinia virus is a very powerful antagonist of TLRs through at least two proteins, A46 and A52. A46 contains a TIR domain which associates with the TIR domain of the adaptor proteins MyD88, Mal, TRIF and TRAM and prevents their recruitment to their dedicated TLR ([@bib0865]). A52 targets TRAF6 and IRAK-2 and limits the activation of the NF-κB pathway in response to several TLRs including TLR4 ([@bib0330]). Hepatitis B virus negatively regulates the expression of TLR2 ([@bib0980]). In the cytoplasm of infected cells, the activity of RLRs is a common target for viral inhibitors. Several viral proteins like NS1 of influenza, VP35 of Ebola, σ3 of reovirus, σA of avian reovirus or E3L of vaccinia virus share the same ability to bind and sequester viral RNAs that are responsible for the activation of RIG-I and MDA5 ([@bib0400], [@bib0415], [@bib0610], [@bib0960]). Through the same mechanism, most of these proteins also inhibit the activation of PKR and the OAS system. The RLRs and the adaptor protein MAVS are also directly targeted by viral proteins. For example, NS1 of influenza associates with RIG-I and inhibits its transactivation function ([@bib0695], [@bib0650]). The interaction of the V protein of paramyxoviruses with the helicase domain of MDA5 blocks the activation of NF-κB and IRF-3 signalling pathways ([@bib0025], [@bib0140]). The 3ABC precursor of 3C(pro) protease of hepatitis A virus and the NS3/4A proteases of HCV and GBV-B cleave MAVS at its carboxy-terminus to interfere with its mitochondrial localization which is crucial for its antiviral function ([@bib0645], [@bib0135], [@bib1015]). IRF-3 and IRF-7 transcription factors, which are essential to ensure IFN-α/β gene expression, also constitute interesting targets for viruses. The phosphoproteins of several negative-strand RNA viruses prevent IRF-3 activation by TBK1. For example, the P protein of Borna virus is phosphorylated by TBK1 and serves as viral decoy for IRF-3 phosphorylation ([@bib0965]). Another intriguing strategy used by human herpes virus 8 resides in the synthesis of viral analogues of IRFs (vIRFs) which act as dominant negative on the action of cellular IRFs through a molecular mimetic mechanism ([@bib0535], [@bib0565]). Alternatively, some viral proteins favour the degradation of IRFs ([@bib0310], [@bib0315]). For example, NSP1 of rotavirus interacts with IRF-3, IRF-5 and IRF-7 and provokes their degradation through the proteasome ([@bib0045], [@bib0050], [@bib0540]). More recently, it was shown that truncated forms of NSP1 from the OSU and SA11 strains are unable to trigger IRF degradation but can still interfere with type I IFN synthesis by interacting with RIG-I ([@bib0725]). The protein ICP0 of HSV interacts and sequesters IRF-3 inside nuclear bodies to prevent binding to its target DNA ([@bib0630]).

### 1.2.2. Inhibition of type I IFN response {#sec0055}

Many viral antagonists interfere with the JAK/STAT pathway to block the synthesis of antiviral proteins such as PKR, Mx and OAS and the induction of antiviral responses. Interestingly, by blocking this signalling pathway, viruses also inhibit the expression of ISGs such as RIG-I, MDA5 or IRF-7 and subsequently interfere with the positive feedback loop triggered by the IFN response to enhance its effect. Some viral proteins act upstream of the JAK/STAT pathway by interfering with the binding of type I IFN to its receptor. For example, the vaccinia virus protein B18R, a soluble homologue of IFNAR, binds type I IFN to block its antiviral effect ([@bib0160], [@bib0880]). JAKs and STATs are more frequently targeted and many viruses can sequester them, induce their degradation or interfere with their phosphorylation or their transport. Human Metapneumovirus has been shown to decrease the cellular levels of JAK1 and TYK2 and the surface expression of IFNAR ([@bib0745]). Rotaviruses are also able to interfere with STATs. A study has shown that monkey rotavirus RRV and human rotavirus Wa were able to block the nuclear translocation of STAT1 and STAT2 in response to type I IFN but not their phosphorylation ([@bib0370]). Some viruses act downstream of the JAK/STAT pathway by interfering with IRF9 and the formation of the ISG3 complex. For example, reovirus is able to inhibit type I IFN response in a strain-dependent manner. μ2 from a strain causing mild myocarditis is able to induce a nuclear accumulation of IRF9 but not μ2 from a non-myocarditic reovirus strain ([@bib1070]). This effect suggests that the viral protein modulates the interaction between IRF9 and STAT and the function of ISG3. Some viruses are also able to target the expression of specific ISGs. For example, HCV infection up-regulates the expression of microRNA miR-130A that targets the expression of the antiviral protein interferon-induced transmembrane 1 (IFITM1) ([@bib0070]). Finally, some viruses are able to induce the expression of regulatory proteins such as PTP, SOCS and PIAS that negatively modulate the JAK/STAT pathway. For example, influenza A virus inhibits the JAK/STAT pathway *via* the induction of SOCS-3 ([@bib0685], [@bib0720]).

### 1.2.3. Inhibition of IFN-induced antiviral factors {#sec0060}

Viruses are also able to target the antiviral factors synthesized in response to type I IFN to promote their replication and survival. By interfering with ISG proteins such as PKR and OAS/RNase L, viruses are able to block their function as sensors of viral infection, to inhibit the production of IFN and consequently to down-regulate their expression. Viral antagonists can target the activity of PKR by acting as pseudo-substrates, by interacting directly with the cellular protein or by inducing its degradation. For example, E2 from HCV contains a homologue sequence to PKR and eIF2α phosphorylation sites and is able to bind PKR and inhibit its kinase activity ([@bib0905]). Reovirus σ3 and σA inhibit the dsRNA-dependent kinase activity of PKR ([@bib0400], [@bib1035], [@bib0610], [@bib0285]). Influenza virus uses another mechanism and activates p58^IPK^, a cellular inhibitor of PKR ([@bib0525], [@bib0530], [@bib0635], [@bib0290]). Several viruses also interfere with the OAS/RNase L system using different mechanisms. Some viruses such as human immunodeficiency virus and EMCV induce the expression of the cellular RNase L inhibitor (RLI) ([@bib0605], [@bib0600]). Rotavirus VP3 contains a phosphodiesterase that cleaves 2-5A to prevent the activation of RNAse L ([@bib1040]). Other ISGs can also be targeted by viruses. For example, it has been shown that the nsp3 papain-like protease (PLP) 2 domain of a human coronavirus is able to deconjugate ISG15 from cellular substrates ([@bib0145]). It was also suggested that membranous structures induced by the Kunjin strain of West Nile virus act as protection for the virus to hide partially from MxA ([@bib0365]) and that the adenovirus E4 ORF3 protein induces a rearrangement of PML nuclear bodies and interferes with the induction of a PML-dependent antiviral response ([@bib0950], [@bib0945]).

2. Induction of type I IFN synthesis by BTV {#sec0065}
===========================================

Most viruses are able to induce IFN synthesis although this event can vary greatly depending on the virus and host features. It is known that for RNA viruses, dsRNA are synthesized as intermediates of replication that represent a major PAMP. For dsRNA viruses, such as members of the *Reoviridae* family, the genome itself is composed of dsRNA molecules that have the ability to activate cellular sensors. In 1967, [@bib0935] first demonstrated that the viral genome of a dsRNA virus, *i.e.* reovirus, was sufficient to induce IFN production. Bluetongue virus (BTV), a dsRNA virus from the *Reoviridae* family, has been described for many years as a strong inducer of IFN. Here we review the current knowledge regarding the ability of BTV to induce type I IFN and the mechanisms and cellular pathways involved.

2.1. BTV induces type I IFN production both *in vitro* and *in vivo* {#sec0070}
--------------------------------------------------------------------

In 1969, Hendrik Huismans from the Onderstepoort Veterinary Research Institute in South Africa infected primary embryonic murine cells with an attenuated American vaccine strain of BTV serotype 10 (BTV-10A) ([@bib0395]). At different time post-infection (p.i.), cell supernatant was collected to measure the IFN titre in the medium of these infected cells. The presence of IFN was detectable as soon as 5 h p.i. and increased until 24 h p.i. This constituted the first evidence of *in vitro* IFN production in response to BTV infection. In the following years, BTV was reported to induce IFN in many cell types from various tissues and species including foetal and adult leukocytes and spleen cells from sheep ([@bib0750]), endothelial cells from bovine and ovine origin ([@bib0150], [@bib0775], [@bib0125]) and kidney cells from rabbits, hamsters, monkeys, cats and pigs ([@bib0430], [@bib0250], [@bib0910]). Importantly, BTV was also shown to induce the production of IFN in multiple human cells with a high efficiency particularly in tumour-derived cell lines ([@bib0420], [@bib0425], [@bib0430], [@bib0440], [@bib0125]).

The initial demonstration of IFN production upon BTV infection was obtained with an attenuated strain (BTV-10A) ([@bib0395]). The potent IFN induction ability of this vaccine strain was latter confirmed by other groups ([@bib0435], [@bib0440]) but [@bib0575] later found that this strain induced low IFN level in comparison with field strains of BTV-2, 4 and 6. Huismans used other attenuated (A) or virulent (V) serotypes (BTV-8A, BTV-1A and BTV-1V) and found that BTV-8A was the best IFN inducer while BTV-1A/V poorly induced IFN synthesis. However, this lack of production could be due to an impaired infectivity of BTV-1A/V in mouse embryonic cells ([@bib0395]). In another study, Fulton and Pearson observed that strains from BTV-10, 11, 13 and 17 could also efficiently induce IFN synthesis. Recently, we found that European field strains of BTV-4 and BTV-8 are strong IFN-β inducers in bovine and human cells ([@bib0125]). Overall, it seems that both attenuated and virulent strains induce IFN and that many if not all serotypes can induce IFN, suggesting that a conserved mechanism of induction exists among the different BTV serotypes and strains.

Using different amounts of virus, H. Huismans initially defined a multiplicity of infection (MOI) of 1 PFU/cell as the minimum input required to obtain detectable levels of IFN and he observed a linear increase between IFN level and virus titre until an MOI of 10 ([@bib0395]). However, this linear correlation between IFN yields and viral titre is not systematically observed and might depend on BTV strains, cell types and/or experimental conditions ([@bib0575]). Upon infection of A549 cells with different amounts of BTV-8 and BTV-4, we observed a strong correlation between the level of IFN-β mRNA and the quantity of virus used ([@bib0125]).

*In vivo* IFN synthesis during BTV infection was initially demonstrated after intravenous injection of 4 × 10^8^  PFU of partially purified BTV-10V in mice ([@bib0395]). IFN synthesis was assessed in blood samples collected at different time p.i. and was detected as early as 4 h p.i. Maximum titre was reached between 8 and 12 h p.i. and then decreased to undetectable level at 24 h p.i. The same result was found with highly purified BTV-10A ([@bib0395], [@bib0210]). [@bib0435] performed a similar experiment few years later and found that injection of 10^6.8^  PFU of BTV in mice induced a rapid production of IFN that reached a peak at 8 h post-injection. Although BTV can infect newborn mice, an adult mouse model was required to study the acquired immune response to BTV and prophylactic approaches. Blocking IFN-α/β activity in mice increases dramatically the sensitivity to many viruses. Indeed, genetically targeted (knockout) mice lacking the β subunit of the IFN-α/β receptor (IFNAR^(−/−)^ mice) are unable to establish an antiviral state and, as a consequence, are highly susceptible to many viral infections ([@bib0655], [@bib0225]). Recently, Calvo-Pinilla et al. showed that adult IFNAR^(−/−)^ mice support the growth of BTV *in vivo*, reproducing many aspects of its natural host infection, and were prone to respond to vaccine strategies ([@bib0110], [@bib0115], [@bib0105], [@bib0100]). Thus, IFNAR^(−/−)^ mice represent a good small animal surrogate model to study BTV pathogenicity and to evaluate vaccine strategies against this virus.

Domestic and wild ruminants are natural targets of BTV infection. To address whether BTV induces IFN in its hosts, several experimental infections were conducted in sheep and cattle. It has been shown that bovine foetuses experimentally infected as early as 125 days of gestation with BTV-10 can produce IFN both in serum and tissues and that this production might limit virus spread within infected tissues ([@bib0580]). In calves infected experimentally with a BTV-10 strain, production of circulating IFN persisted between 2 and 4 days post-infection with a peak between 1 and 3 days p.i. ([@bib0585]). Titres of BTV measured in the blood were higher when IFN was no longer detectable in serum collected at the same time. This early transient synthesis of IFN suggests a preponderant role in the initial antiviral response rather than an involvement in the subsequent elimination of the infection. In sheep, IFN was detected in the serum of animals infected with BTV-10, -11, -13 and -17 (American strains) 5 days p.i. and peaked at day 6 p.i., which correlated with a first peak of viraemia ([@bib0235]). In comparison to the IFN antiviral response detected in cattle, the IFN index in sheep was higher and lasted longer. The IFN peak correlated with a 90% reduction in the viral titre. The decrease in IFN level was concomitant with a second peak of viraemia at day 10 p.i. Diphasic viraemia could be attributed to the induction of high levels of IFN concomitantly to a first peak of viral titre, followed by the production of specific antibodies and a subsequent reduction of the viraemia during the second peak.

At the cellular level, it has been shown that BTV targets cDCs and pDCs early after infection in sheep ([@bib0340], [@bib0770]). Interestingly, inoculation of an attenuated strain of BTV-2 (a-BTV-2) and a wild-type strain of BTV-8 (BTV-8) in the skin of sheep induced IFN-α/β production in afferent lymph, peaking at day 6 p.i. with a-BTV-2 (16 IU/ml) and at day 5 p.i. with BTV-8 (12 IU/ml), which corresponds to the peak of cDC-dependent viral dissemination from the skin ([@bib0340]). Circulating IFN-α/β was also found in the blood of sheep inoculated with BTV-8 at days 2 and 6 p.i. These results suggest that lymph and blood pDCs and/or cDCs can be activated by BTV to produce IFN-α/β as both pDCs and cDCs are found in blood and lymph in sheep ([@bib0680]). Enrichment of lymph and blood cells in cDCs and pDCs by low-density (LD) gradient centrifugation lead to IFN-α/β synthesis upon BTV stimulation independently of BTV strain and attenuation. In order to identify the cell type that was responsible for the IFN-α/β produced by the LD lymph and blood cells after BTV stimulation, cDCs (CD11c^+^ cells) and pDCs (B^−^ CD11c^−^ CD45RB^+^ cells) were isolated using immunomagnetic beads ([@bib0680]) and were subsequently subjected to BTV-2 stimulation. No IFN-α/β was detected in the lymph CD11c^+^ cell fraction in response to BTV-2, while high levels were measured in the CD11c^−^ cell fraction. Sheep lymph pDCs were then isolated and were found to produce IFN-α/β upon exposure to a-BTV-2. In blood, only CD45RB^+^ cells were also able to synthesize IFN-α/β following BTV exposure. Altogether, these findings show that pDCs are the main producers of IFN-α/β upon BTV infection among immune cells. However, in other viral infections, pDCs are responsible for a burst of IFN-α/β within the first 24 h, a time frame that remains to be investigated in BTV infection *in vivo* ([@bib1065]).

Besides IFN production, BTV induces an inflammatory response which results in the synthesis of many inflammatory cytokines and co-stimulatory molecules which have an impact on the immune response triggered by the virus. In addition, several studies have indicated that a strong correlation exists between BTV-induced inflammatory cytokines and the pathogenesis of the disease ([@bib0185], [@bib0190]). This is further discussed in the review from James MacLachlan published in this issue. In A549 cells, we found that the expression of IL-8 mRNA, a pro-inflammatory cytokine whose induction is predominantly dependent on NF-κB, is induced upon BTV infection and is concomitant with the expression of IFN-β mRNA ([@bib0125]). [@bib0770] have found that BTV can induce the expression of multiple cytokine genes like TNF-α, IL-6 and IL-12, as well as surface CD80/86, in purified primary sheep blood pDCs *in vitro*. Furthermore, upon *in vivo* infection, sheep blood pDCs displayed a strong inflammatory gene expression profile, with up-regulation of CCL2, CCL4, IL-8, IFN-γ and TNF transcripts ([@bib0765]).

2.2. Mechanisms involved in the production of type I IFN production by BTV {#sec0075}
--------------------------------------------------------------------------

As described above, IFN induction by BTV has been greatly documented *in vivo* and *in vitro* but the underlying mechanisms of this induction were unknown for a long time. Recent data have shed light on the cellular events required for activation of this antiviral response during BTV infection.

### 2.2.1. BTV PAMPs {#sec0080}

One important question regarding IFN induction is the type of PAMPs that triggers this induction. As early as 1967, it was shown that the dsRNA genome of *Reoviridae* is a potent inducer of IFN synthesis ([@bib0935]). Soon after, it was shown that injection of 8 μg of dsRNA isolated from BTV-10A in mice induced IFN synthesis after a 2 h latency phase and reached a maximum 6 h post-injection. This peak preceded of about 4 h the one obtained after infection with the corresponding virus ([@bib0395], [@bib0210]). This delay might correspond to the time needed for decapsidation, release of viral genome or synthesis of new dsRNA. In preliminary experiments, we found that transfection of cells with purified BTV dsRNA activated IFN-β promoter (not shown). These data suggest that viral dsRNA of BTV genome is sufficient to trigger IFN synthesis both *in vivo* and *in vitro*.

The need for replication to induce IFN synthesis upon BTV infection has been extensively addressed *in vitro* and *in vivo* but remains unclear. [@bib0435] first suggested that, in mice, IFN synthesis occurs independently of the production of viral progeny as a UV-inactivated BTV induced similar levels of IFN as an infectious virus. *In vitro*, [@bib0910] observed that IFN production was effective in rabbit cells infected with a UV-inactivated vaccine strain from serotype 10. This was confirmed in the human cell line HT-1376 which produced high amount of IFN after BTV infection. In these cells, infectious and UV-inactivated BTV (MOI of 10 PFU/cell) induced comparable level of IFN ([@bib0425]). In contrast, they also observed that a UV-inactivated virus used at an MOI of 50 induced low level of IFN in the A375 human cell line. H. Huismans previously suggested that IFN production is not linked to replication efficiency as BTV-8A, which replicates at lower level than BTV-10A, induced more IFN ([@bib0395]). Similarly, we found that while BTV-8 seemed to replicate more efficiently than BTV-4 in A549 cells at 48--72 h p.i., the BTV-4 strain induced more strongly the synthesis of IFN than BTV-8 at 36--48 h p.i. ([@bib0125]). In A549 cells infected with BTV-8, we also observed that the level of IFN-β mRNA followed the kinetic of BTV RNA synthesis, suggesting that viral replication is required to trigger IFN-β synthesis. Unlike live BTV-8, we found that the levels of IFN-β mRNA and protein quantified in cells infected with the UV-inactivated virus were close to background level, indicating that virus replication is essential for IFN-β induction in A549 cells ([@bib0125]). Similar results were obtained in the bovine cell line MDBK.

In pDCs, IFN-α/β production usually occurs independently of viral replication but exceptions do exist ([@bib0385], [@bib0295]). In a recent work, [@bib0770] found that active BTV infection occurs in sheep pDCs (see above). When UV-inactivated BTV-8 was used, IFN-α/β was still produced in the supernatant of LD lymph cells and highly purified blood pDCs but at a lower level than with live virus ([@bib0770]). The same results were also found with purified BTV-1 and UV-BTV-1 ([@bib0770]).

### 2.2.2. RIG-I and MDA5 are involved in IFN-β production in BTV-infected epithelial cells {#sec0085}

As mentioned previously in this review, the innate cellular responses activated during viral infections require recognition of PAMPs by PRRs. Several PRRs have been identified for the *Reoviridae* family, including TLR3 ([@bib0020]), RIG-I and MDA5 ([@bib0095], [@bib0835], [@bib1030]), PKR ([@bib0835], [@bib0260]) and the newly described TRIF-dependent DexD/H-box helicases ([@bib1050]). Although BTV has been recognized for many years as a potent inducer of type I interferon (see above), the PRRs and signalling pathways involved in this cellular response remained uncharacterized.

Using A549 cells, we aimed to identify which signalling pathway(s) is triggered by BTV for IFN-α/β synthesis. We used a siRNA approach to silence the expression of MAVS, TLR3, MyD88, TRIF and DDX1 which are critical components of major pathways involved in viral sensing. Upon BTV infection, the expression of IFN-β mRNA expression was severely impaired only after MAVS silencing, indicating that MAVS is involved in IFN-β production following BTV infection ([@bib0125]). As MAVS is an adaptor protein for RIG-I and MDA5 helicases, we assessed the role of these viral RNA sensors in the production of IFN-β during BTV infection. When the expression of RIG-I or MDA5 was silenced with specific siRNA prior to BTV infection, IFN-β mRNA level was significantly reduced in infected cells. These results were confirmed at the protein level using an IFN-β ELISA assay. Interestingly, overexpression of RIG-I, MDA5 or both proteins in A549 cells prior to BTV infection resulted in a decrease in viral RNA, VP5 protein expression and virus titre, highlighting the importance of these sensors to mount an antiviral response towards BTV ([Fig. 1](#fig0005){ref-type="fig"} ).Fig. 1Mechanisms of IFN-α/β induction upon BTV infection in haematopoietic and non-haematopoietic cells. In pDCs, IFN-α/β production involves endo/lysosomal acidification after BTV infection. This synthesis occurs through a TLR7-independent pathway implicating the MyD88 adaptor, PKR and JNK kinases, *via* a new sensor(s) whose identity and subcellular location remain to be determined. In contrast, in non-haematopoietic cells, BTV can activate the RNA helicases RIG-I and MDA5 that trigger a signalling cascade involving the mitochondrial protein MAVS and the subsequent activation of the IRF3 and NF-κB pathways that are both required for IFN-β synthesis.

### 2.2.3. Induction of type I IFN in ovine plasmacytoid dendritic cells occurs *via* a Myd88-dependent pathway {#sec0090}

As depicted above, BTV targets cDCs and pDCs early after infection in sheep and induces IFN-α/β synthesis in pDCs ([@bib0340], [@bib0770]). In order to investigate the mechanism of IFN-α/β induction in pDCs, Ruscanu et al. first addressed whether IFN-α/β induction by UV-BTV required intracellular processing *via* endo-/lysosomal vesicle maturation. Inhibitors of endolysosomal maturation blocked IFN-α/β synthesis, suggesting that a TLR-mediated signalling is involved in IFN-α/β induction after UV-BTV stimulation, as usually observed with pDCs during viral infections. The use of A151, an oligonucleotide described as a TLR antagonist inhibiting TLR7 and, to a lesser extent, TLR9 did not inhibit IFN-α/β induction by UV-BTV, indicating that UV-BTV activates IFN-α/β production *via* a TLR7/8-independent mechanism.

The role of MyD88 adaptor was also investigated as it mediates TLR7 and TLR9 signalling but also TLR-independent pathways ([@bib0485]). LD PBMCs from five different sheep were cultured overnight with a MyD88 inhibitory peptide ([@bib0550]) or a control peptide and then activated with CpG-A or with UV-BTV for 12 h. The MyD88 inhibitory peptide significantly inhibited IFN-α/β synthesis induced by both CpG and BTV, indicating that UV-BTV-dependent IFN-α/β synthesis in pDCs involves, at least partly, the MyD88 adaptor independently of TLR7/8 activation.

Ruscanu et al. also assessed the contribution of the cytosolic serine/threonine kinase PKR in IFN-α/β production induced by UV-BTV as its role in IFN-α/β induction in response to viral infections was not yet known in pDCs ([@bib0195], [@bib0385], [@bib0830], [@bib0835]). After treatment with PKR inhibitors, IFN-α/β production was impaired in LD PBMCs as well as in purified blood pDCs. PKR is known to activate mitogen-activated protein kinases (MAPK) which have also been implicated in the induction of IFN-α/β in response to virus infection ([@bib0280], [@bib0220]). To assess the contribution of this family of kinases, Ruscanu et al. cultured LD PBMCs and purified pDCs with UV-BTV in the presence of specific drugs that target the activity of stress-activated protein kinase (SAPK)/JNK or ERK1/2, two members of the MAPK family. The authors found that UV-BTV IFN-α/β induction was inhibited by the SAPK/JNK inhibitor by over 60%, whereas the ERK1/2 inhibitor had no effect.

Altogether, these data show that the induction of IFN-α/β by UV-BTV in pDCs involves a TLR7/8-independent and MyD88-dependent mechanism. Based on the use of pharmacological inhibitors, they also implicate PKR- and SAPK/JNK-dependent mechanisms ([Fig. 1](#fig0005){ref-type="fig"}).

3. Modulation of the IFN pathway by NS3 of BTV {#sec0095}
==============================================

Production of type I IFN induces a cellular response that is detrimental for viral propagation. In order to dampen this host antiviral response, most of viruses have evolved counteracting strategies. This includes members of the *Reoviridae* family such as rotavirus and reovirus. The ability of BTV to control the IFN pathway has been poorly studied in the past and only recently, a study from our group has shown that BTV is also able to inhibit this antiviral response ([@bib0130]).

The effect of BTV infection on the activation of IFN-β promoter was first assessed using a luciferase reporter assay. 293T cells were infected with a BTV-8 strain isolated in France and transfected 8 h p.i. with a IFN-β reporter plasmid, a control vector and an expression vector coding for a constitutively active form of RIG-I (NRIG-I). IFN-β promoter activation was greatly impaired in BTV-infected cells in comparison to mock-infected cells, showing that BTV-8 is able to inhibit IFN-β promoter activity after stimulation of the RIG-I-like pathway. The impact of the overexpression of the different BTV ORFs on the activity of IFN-β promoter was assessed using the same assay and the Polo-like kinase 1 Polo-box domain (Plk1-PBD), an antagonist of the RLR pathway, was used as control ([@bib0985]). The strongest inhibitory effect on IFN-β promoter activity was achieved in cells expressing the viral protein NS3. This effect was conserved between field and attenuated strains from different BTV serotypes. Indeed, live South African vaccine strains of BTV-2 and -4 were also able to block this activation. Furthermore, we showed that NS3 reduced the level of IFN-β mRNA transcripts upon activation with NRIG-I, confirming that NS3 affects the transcription of *IFN-β* gene at the endogenous level. NS3 was also able to block the activation of IFN-β promoter induced by other stimuli of the RLR pathway, including Sendai virus (RNA virus), poly(I:C) (synthetic dsRNA) or poly(dA/dT) (transcribed to dsRNA by RNA polymerase III). Interestingly, NS3 had no effect on the activity of an *in vitro*-transcribed mRNA encoding the luciferase protein, suggesting that NS3 does not interfere with translation. NS3 had no effect on the activity of a CMV promoter and a promoter dependent on c-jun, a transcription factor involved in the expression of multiple genes, showing that NS3 did not induce a complete host transcriptional shutoff. However, it is still possible that NS3 affect a broad range of promoters.

In order to identify at which level of the RLR pathway NS3 acts, the effect of NS3 on the ability of overexpressed MAVS, TBK1, IKKɛ and IRF-3 5D (a constitutively active form of IRF-3) to activate IFN-β promoter was assessed in the same study. Results from this experiment showed that NS3 interferes with the IFN synthesis pathway downstream RIG-I and upstream TBK1/IKKɛ activation.

4. Conclusions {#sec0100}
==============

BTV is a major animal health concern but remains poorly characterized especially when it comes to the understanding of how the virus interacts with the immune innate response. BTV is a strong inducer of IFN-α/β, a key player of the innate antiviral response, in many cells types including endothelial and epithelial cells of bovine and human origin. In non-haematopoietic cells, the viral RNA sensors RIG-I and MDA5 are upregulated by BTV infection and these helicases control both the sensing and the pro-inflammatory and anti-viral responses to BTV. In contrast, BTV activates the IFN-α/β signalling pathway in pDCs *via* the MyD88 adaptor, independently of TLR7/8, and *via* a mechanism implicating PKR and JNK kinases. These data suggest for the first time that a dsRNA virus can trigger IFN-α/β in primary host pDCs *via* a mechanism independent on TLR7/8 but dependent on MyD88. Deeper mechanistic investigations should be undertaken to discover additional viral sensors in pDCs that would be pertinent for dsRNA viruses and possibly other pathogens.

The discrepancy between the sensors and signalling cascades activated by BTV in immune *versus* non-immune cells could be explained by the fact that different cellular responses exist in these cells. It is possible that, during the first stage of infection, a strong systemic production of type I IFN and other cytokines is induced in specialized antigen presenting cells (mainly pDC) through a replication- and RLR-independent mechanism and later, in the main target cells of BTV infection, such as endothelial cells, distinct PRRs respond to products of BTV replication to trigger a tissue-localized antiviral response ([Fig. 1](#fig0005){ref-type="fig"}). These findings help in the understanding of the pathogenesis associated with BTV infection and, importantly, facilitate the development of better vaccines against dsRNA viruses. For example, they suggest that industrial processes of viral inactivation must maintain the ability of BTV and/or other members of the *Reoviridae* family to trigger type I IFN production by pDCs in order to induce optimal adaptive responses after vaccination. Indeed, type I IFN production by pDCs has recently been shown to be essential for the induction of high antibody titres upon rotavirus infection ([@bib0180]).

In this review, we also discussed evidences given on the ability of NS3 of BTV to interfere with the induction of the innate immune response in non-haematopoietic cells by inhibiting the RLR-dependent signalling pathway. Thus, as most viruses, BTV has evolved at least one strategy to interfere with the production of type I IFN. NS3 was shown to modulate the induction of type I IFN but it is possible that other genes/pathways are affected by this viral protein. The mode of action of NS3 remains poorly characterized and further studies need to be undertaken to fully understand the different functions of this viral protein. Some other viral proteins might also interfere with host antiviral responses and the IFN system. In a reporter assay, NS3 was shown to be the strongest inhibitor of IFN-β promoter activation but other proteins also displayed antagonistic activity although to a lesser extent ([@bib0130]). Moreover, an additional protein encoded by BTV, NS4, has been recently discovered and is thought to interact with the IFN pathway ([@bib0735]).

Interestingly, in another study, several BTV proteins including VP1, VP2 and NS2 were suggested to be determinants of virulence as the genome encoding these proteins consistently showed non-synonymous changes between virulent and attenuated BTV strain pairs ([@bib0120]). It would be of great interest to investigate further whether these virulent factors contributing to viral pathogenesis are able to modulate the strength of type I IFN signalling and to precise the putative role of some other viral proteins in the control of this response ([@bib0875], [@bib0735]). The understanding of the interplay between BTV and the IFN pathway is only at its beginning and many unknowns remain to be addressed.
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